Clarity Presents New Prostate Cancer Imaging Data at Global Urology Congress
Clarity Pharmaceuticals Limited (ASX: CU6) reported that findings from the Co-PSMA clinical study were presented at the European Association of Urology Annual Congress 2026 in London, with the research also accepted for publication in the journal European Urology. The research compared the company’s imaging agent 64Cu-SAR-bisPSMA with the standard tracer 68Ga-PSMA-11 in men whose prostate cancer had returned following surgical treatment.
The trial involved 50 participants with low prostate-specific antigen levels and assessed how effectively each imaging approach identified recurrent disease. Results indicated that the 24-hour scan using 64Cu-SAR-bisPSMA detected a greater number of lesions and produced a higher proportion of positive scans compared with the standard tracer. The improved detection capability also influenced clinical decision-making, with treatment strategies adjusted for a notable portion of participants.
These findings add to the broader clinical evidence supporting the technology and may contribute to future regulatory submissions for the imaging agent in prostate cancer recurrence.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Clarity Presents New Prostate Cancer Imaging Data at Global Urology Congress
Clarity Pharmaceuticals Limited (ASX: CU6) reported that findings from the Co-PSMA clinical study were presented at the European Association of Urology Annual Congress 2026 in London, with the research also accepted for publication in the journal European Urology. The research compared the company’s imaging agent 64Cu-SAR-bisPSMA with the standard tracer 68Ga-PSMA-11 in men whose prostate cancer had returned following surgical treatment.
The trial involved 50 participants with low prostate-specific antigen levels and assessed how effectively each imaging approach identified recurrent disease. Results indicated that the 24-hour scan using 64Cu-SAR-bisPSMA detected a greater number of lesions and produced a higher proportion of positive scans compared with the standard tracer. The improved detection capability also influenced clinical decision-making, with treatment strategies adjusted for a notable portion of participants.
These findings add to the broader clinical evidence supporting the technology and may contribute to future regulatory submissions for the imaging agent in prostate cancer recurrence.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au